The present invention relates to pharmaceutical compositions comprising lipid-bacteriophage conjugates, wherein the bacteriophage:lipid ratio is comprised between 3:1 to 100:1 and wherein the lipid is an immunologically active lipid and the bacteriophage is a filamentous bacteriophage, and uses thereof. Preferably, the bacteriophage is engineered to stimulate an immune response and/or bind to a target cell

PHAGE CONJUGATES AND USES THEREOF

Piergiuseppe De Berardinis;Rossella Sartorius
2023

Abstract

The present invention relates to pharmaceutical compositions comprising lipid-bacteriophage conjugates, wherein the bacteriophage:lipid ratio is comprised between 3:1 to 100:1 and wherein the lipid is an immunologically active lipid and the bacteriophage is a filamentous bacteriophage, and uses thereof. Preferably, the bacteriophage is engineered to stimulate an immune response and/or bind to a target cell
2023
Istituto di Biochimica e Biologia Cellulare - IBBC
Filamentous Bacteriophage
alpha-Galactosylceramide
iNKT
antitumor immunity
immunotherapy
File in questo prodotto:
File Dimensione Formato  
US11744901.pdf

non disponibili

Tipologia: Altro materiale allegato
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.55 MB
Formato Adobe PDF
1.55 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/451627
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact